Investor Relations

Investor Relations

Investor Relations

Company Overview

We are a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer. We apply our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.

Learn more

Data Provided by Refinitiv. Minimum 15 minutes delayed.

View Stock information

ProTide Technology

We harness the power of phosphoramidate chemistry to develop next-generation chemotherapeutics designed to overcome the key cancer resistance mechanisms of existing nucleoside analogs.

Discover More
molecular structure

Latest Annual Report

NuCana Annual Report - 2021

View Our Report

Corporate Presentation

NuCana Presentation - July 2024

View Our Preesentation